問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chi Mei Medical Center (在職)

Division of Hematology & Oncology

Chi Mei Hospital, Liouying (在職)

Division of Hematology & Oncology

Chi Mei Medical Center (在職)

Division of Hematology & Oncology

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Chi Mei Medical Center (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

吳鴻昌
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

65Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳鴻昌

List

89Cases

2021-04-01 - 2026-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Not yet recruiting17Sites

2022-04-01 - 2026-12-31

Phase II

A Phase 2 Study to Evaluate the Safety and Immunological Efficacy of Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients with HER2 Expressing Gastric Cancer (CORNERSTONE-003)

  • Condition/Disease

    Stomach cancer

  • Test Drug

    AST 301/pNGVL3 hICDLEUKINE® (sargramostim)

Participate Sites
6Sites

Recruiting6Sites

2018-03-01 - 2023-12-31

Phase III

A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    Atezolizumab; Bevacizumab; Sorafenib

Participate Sites
5Sites

Terminated5Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2021-07-01 - 2022-08-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting2Sites

Terminated1Sites

2011-07-01 - 2013-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Study ended11Sites

2022-03-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2016-06-07 - 2020-03-31

Phase II

A Phase 2a Study to evaluate the clinical efficacy of JNJ-42756493(erdafitinib), a pan-Fibroblast Growth Factor Receptor (FGFR) tyrosine kinase inhibitor, in Asian patients with advanced non-small-cell lung cancer, urothelial cancer, esophageal cancer, or cholangiocarcinoma.

  • Condition/Disease

    advanced non-small-cell lung cancer, urothelial cancer, esophageal cancer, or cholangiocarcinoma

  • Test Drug

    JNJ-42756493

Participate Sites
6Sites

Not yet recruiting1Sites

Terminated4Sites

Study ended1Sites

2013-12-01 - 2016-12-31

Phase III

A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancer

  • Condition/Disease

    Colorectal cancer

  • Test Drug

    Masitinib

Participate Sites
5Sites

Terminated5Sites

2016-01-01 - 2016-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2014-07-01 - 2017-12-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 5 6 7 8 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB